Interestingly, we did not observe a similar phenomenon for DR5; indeed, CD13 inhibitor treatment did not increase the cell surface levels of DR5 in the tested cells under the same conditions, thus suggesting that DR5 may not be functionally necessary for the synergistic anti-tumor effects of TRAIL and CD13 inhibition in this study. This evidence concerns the gene ANPEP and neoplasm.